25975-59-1

Basic information

• Product Name: 5-ANDROSTENEDIOL
• Synonyms: 19-NOR-5-ANDROSTENEDIOL;ANDROSTENDIOL;ANDROSTENEDIOL, 5-;(3S,8R,9S,10R,13S,14S,17S)-10,13-DIMETHYL-2,3,4,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17-DIOL;5-ANDROSTEN-3-BETA, 17-BETA-DIOL;5-ANDROSTENE-3BETA,17BETA-DIOL;5-ANDROSTENEDIOL;5-ANDROSTENEDIOL, 10,13-DIMETHYL-2,3,4,7,8,9,11,12,14,15,16,17-DODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
• CAS NO: 25975-59-1
• Molecular Formula: C₁₈H₂₈O₂
• Molecular Weight: 290.44
• Product Categories: Miscellaneous Biochemicals;Steroids
• Mol File: 25975-59-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 152-157 °C(Solv: ethanol, 95% (64-17-5))
• Boiling Point: 429.2 °C at 760 mmHg
• Flash Point: 198.3 °C
• Appearance: /
• Density: 1.14 g/cm³
• Vapor Pressure: 3.64E-09mmHg at 25°C
• Refractive Index: 1.573
• PKA: 15.00±0.60(Predicted)
• CAS DataBase Reference: 5-ANDROSTENEDIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ANDROSTENEDIOL(25975-59-1)
• EPA Substance Registry System: 5-ANDROSTENEDIOL(25975-59-1)

Safety Data

• Hazardous Substances Data: 25975-59-1(Hazardous Substances Data)

Usage

Description

5-ANDROSTENEDIOL, also known as 9-Nor-5-androstene-3β,17β-diol, is a synthetic anabolic steroid derived from the C19-steroidal class. It possesses the ability to interact with androgen receptors, making it a subject of interest in various research and medical applications.

Uses

Used in Pharmaceutical Industry:
5-ANDROSTENEDIOL is used as a pharmaceutical compound for its potential role in the treatment of prostate cancer. It functions as a C19-steroidal androgen receptor modulator, which has been studied for its effects on androgen receptors, potentially offering a new approach to managing prostate cancer.
Additionally, due to its anabolic steroid properties, 5-ANDROSTENEDIOL may also be used in the development of other therapeutic applications related to androgen receptor interactions, although further research is needed to explore these possibilities.

InChI:InChI=1/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,12-17,19-20H,3-10H2,1H3/t12?,13-,14+,15+,16-,17?,18-/m0/s1

Upstream product

• 4999-76-2 3,17β-diacetoxyoestra-3,5-diene 
• 70286-48-5 3-acetoxy-19-nor-androsta-3,5-dien-17-one 
• 434-22-0 19-nortestosterone 
• 109-99-9 tetrahydrofuran 
• 64-17-5 ethanol 
• 42028-18-2 17β-hydroxyestr-5-en-3-one 
• 734-32-7 estra-4-ene-3,17-dione 
• 31321-37-6 3β,17β-diacetoxy-19-norandrost-5-ene 

Downstream Products

• 50-28-2 estradiol 
• 571-92-6 6-ketoestradiol 

Relevant articles and documents

OXIDATIVE β-FRAGMENTATION OF 19-NOR-5α-ANDROSTANE-3β,5,17β-TRIOL 3,17-DIACETATE

The preparation of 19-nor-5α-androstane-3β,5,17β-triol 3,17-diacetate (10) is described.When this alcohol was treated with the mercuric oxide-iodine reagent, it underwent fragmentation of the C(5)-C(10) bond with formation of a new type of 10-membered ring containing 5,10-seco-steroidal compounds, i.e. (Z)-and (E)-19-nor-3β,17β-diacetoxy-5,10-seco-androst-1(10)-en-5-one (11 and 12), in 27 and 49percent yield, respectively.

PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.